Proassurance CORP 8-K filings

ProAssurance Corporation has finalized its merger with The Doctors Company, resulting in its transition to a wholly owned subsidiary and subsequent delisting from the NYSE.

ProAssurance Corporation provides an update on its pending merger with The Doctors Company, confirming significant regulatory approvals and reiterating an anticipated closing date.

ProAssurance Corporation announced first quarter 2026 results, reporting net income of $8.5 million and operating income of $12.7 million, while continuing to navigate regulatory approvals for its merger with The Doctors Company.

ProAssurance Corporation announced significant increases in operating income and improved combined ratios for Q4 and full-year 2025, alongside continued progress on its merger with The Doctors Company.

ProAssurance Corporation's Compensation Committee approved cash incentive awards for named executive officers to mitigate potential Section 280G impacts ahead of its merger with The Doctors Company.

ProAssurance reported a significant drop in Q3 net income but saw improved nine-month operating income and advanced its merger with The Doctors Company.

ProAssurance Corporation reported a significant increase in net and operating income for the second quarter of 2025, alongside substantial improvements in its combined ratio and progress on its merger with The Doctors Company.

ProAssurance Corporation and The Doctors Company announced the early termination of the Hart-Scott-Rodino waiting period, satisfying a significant condition for their pending merger expected to close in the first half of 2026.

ProAssurance Corporation's stockholders have overwhelmingly approved the proposed acquisition by The Doctors Company, paving the way for the transaction to close in the first half of 2026, subject to regulatory approvals.

ProAssurance held its Annual Meeting of Stockholders on May 21, 2025, electing three new directors and making changes to the Audit Committee.

ProAssurance Corporation reported a net loss of $5.8 million for the first quarter of 2025, while also highlighting progress in premium rate adjustments and an agreement to be acquired by The Doctors Company.

ProAssurance Corporation has entered into a definitive agreement to be acquired by The Doctors Company for $25.00 per share in cash.

The Doctors Company will acquire ProAssurance for $25.00 per share in cash, representing a 60% premium to the closing price on March 18, 2025.

ProAssurance Corporation reports net income of $16.2 million for Q4 2024 and $52.7 million for the full year, signaling progress in profitability.

ProAssurance Corporation reported a net income of $16.4 million for the third quarter of 2024, driven by improved underwriting performance and increased investment income.

ProAssurance reported a net income of $15.5 million for the second quarter of 2024, driven by strong investment income and improved underwriting results.

ProAssurance announced the election of two new directors, Richard J. Bielen and Staci M. Pierce, at its annual shareholder meeting and provided an update on its first quarter 2024 financial results.

ProAssurance Corporation held its annual meeting, electing four new directors, approving a new equity incentive plan, and ratifying its independent auditor.

ProAssurance Corporation reported a net income of $4.6 million for the first quarter of 2024, showing improvement in key financial metrics.

ProAssurance Corporation reports the results of its 2023 Annual Stockholder Meeting, including the re-election of four directors and the ratification of the independent auditor.

ProAssurance Corporation has filed a Form 8-K to correct a typographical error in its 2023 Annual Report regarding the number of securities available for future issuance under equity compensation plans.

ProAssurance's investor update outlines strategic shifts, financial results, and future plans, emphasizing a return to sustained profitability.

ProAssurance Corporation reported a net income of $6.4 million for the fourth quarter of 2023, alongside an operating loss of $2.5 million, as the company navigates challenging market conditions and rising claim costs.